

# Cellmid Limited

08:53 11 Jun 2019

## Cellmid MD and CEO demonstrates confidence through further on-market share purchase

Cellmid Ltd managing director and CEO Maria Halasz has purchased shares on-market in a further show of confidence in the company's life sciences strategy.

On May 31 Halasz purchased a further 12,000 shares in the company in an on-market trade and now holds almost 2.2 million shares in direct and indirect interests.

### READ: Cellmid managing director and CEO lifts holding in life sciences company with on-market purchase

This follows the purchase of 39,000 shares in early May.

Cellmid is an Australian life sciences company with a consumer health business and biotechnology assets in development, which the company is intending to spin out into two entities.

The former includes the évolis hair care products for which the company is expanding distribution on a global basis.

### READ: Cellmid appoints new Lyramid CEO to drive clinical development of midkine assets

Cellmid recently appointed Bart Wuurman, an accomplished biotech chief executive, as CEO of its wholly-owned subsidiary Lyramid.

Wuurman has more than 30 years' experience in innovative drug development, biotech financing, business development and licensing.

He has extensive experience in working with R&D based companies in pharmaceutical product development in several therapeutic areas, including cancer, fibrosis and cardiovascular diseases.

This appointment is in line with Cellmid's strategy to unlock shareholder value by separating the consumer health and the biotech business.

His mandate is to accelerate partnering discussions and explore opportunities to fully exploit the midkine assets.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

**Price:** 0.185

**Market Cap:** \$17.87 m

#### 1 Year Share Price Graph



#### Share Information

**Code:** CDY

**Listing:** ASX

**52 week High Low**  
0.285 0.165

**Sector:** Pharma & Biotech

**Website:** [www.cellmid.com.au](http://www.cellmid.com.au)

#### Company Synopsis:

*Cellmid Ltd (ASX:CDY) is an Australian life sciences company with lead programs in multiple disease&nbsp;indications.*

[action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

## No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).